Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).

Med Chem (Los Angeles) · 2013 · PMC4516389 · PMID 26225219

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an obvious trendno p-value reported

Gemcitabine-(C 4 - amide )-[anti-HER2/ neu ] in combination with griseofulvin (15 μM fixed-concentration) compared to just gemcitabine-(C 4 - amide )-[anti-HER2/ neu ] alone resulted in anti-neoplastic cytotoxicity profiles there were similar but there was an obvious trend for the dual combination to exert greater activity ( Figure 7 ).

also in 1,006 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Anti-Neoplastic Cytotoxicity of Gemcitabine-(C<sub>4</sub>-<i>amide</i>)-[anti-HER2/<i>neu</i>] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).

The sentences